To date, numerous inhibitors of the human immunodeficiency virus type 1 protease have
been reported, but few have been studied extensively in humans, primarily as a consequence …

A series of HIV protease inhibitors possessing a hydroxylaminepentanamide transition state
isostere have been developed. Incorporationof a basic amine into the backbone of the L-…

The increasing incidence of resistance to current HIV-1 therapy underscores the need to
develop antiretroviral agents with new mechanisms of action. Integrase, one of three viral …

Naphthyridine 7 inhibits the strand transfer of the integration process catalyzed by integrase
with an IC 50 of 10 nM and inhibits 95% of the spread of HIV-1 infection in cell culture at …

We describe the development of cell-permeable β-secretase inhibitors that demonstratively
inhibit the production of the secreted amino terminal fragment of an artificial amyloid …

We describe the efficacy of L-870812, an inhibitor of HIV-1 and SIV integrase, in rhesus
macaques infected with the simian-human immunodeficiency virus (SHIV) 89.6P. When initiated …

HCV NS3/4a protease inhibitors are proven therapeutic agents against chronic hepatitis C
virus infection, with boceprevir and telaprevir having recently received regulatory approval as …

The NS5A protein plays a critical role in the replication of HCV and has been the focus of
numerous research efforts over the past few years. NS5A inhibitors have shown impressive in …

Introduction. Human immunodeficiency virus type 1 (HIV-1) is the etiological agent of acquired
immunedeficiency syndrome (AIDS). The unique nature of the replicative cycle of HIV-1 …

A new class of HCV NS3/4a protease inhibitors containing a P2 to P4 macrocyclic constraint
was designed using a molecular modeling-derived strategy. Building on the profile of …